Medexus Pharmaceuticals Stock Net Asset
| MDP Stock | 2.86 0.12 4.38% |
As of the 13th of February 2026, Medexus Pharmaceuticals secures the Risk Adjusted Performance of 0.0476, downside deviation of 2.16, and Mean Deviation of 1.79. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Medexus Pharmaceuticals, as well as the relationship between them.
Medexus Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Medexus Pharmaceuticals' valuation are provided below:Medexus Pharmaceuticals does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Medexus |
Medexus Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Medexus Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Medexus Pharmaceuticals.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Medexus Pharmaceuticals on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Medexus Pharmaceuticals or generate 0.0% return on investment in Medexus Pharmaceuticals over 90 days. Medexus Pharmaceuticals is related to or competes with Cardiol Therapeutics. More
Medexus Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Medexus Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Medexus Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.16 | |||
| Information Ratio | 0.0212 | |||
| Maximum Drawdown | 11.22 | |||
| Value At Risk | (3.60) | |||
| Potential Upside | 4.12 |
Medexus Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medexus Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Medexus Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Medexus Pharmaceuticals historical prices to predict the future Medexus Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0476 | |||
| Jensen Alpha | 0.1002 | |||
| Total Risk Alpha | (0.07) | |||
| Sortino Ratio | 0.0232 | |||
| Treynor Ratio | 0.6727 |
Medexus Pharmaceuticals February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0476 | |||
| Market Risk Adjusted Performance | 0.6827 | |||
| Mean Deviation | 1.79 | |||
| Semi Deviation | 1.96 | |||
| Downside Deviation | 2.16 | |||
| Coefficient Of Variation | 1966.06 | |||
| Standard Deviation | 2.36 | |||
| Variance | 5.57 | |||
| Information Ratio | 0.0212 | |||
| Jensen Alpha | 0.1002 | |||
| Total Risk Alpha | (0.07) | |||
| Sortino Ratio | 0.0232 | |||
| Treynor Ratio | 0.6727 | |||
| Maximum Drawdown | 11.22 | |||
| Value At Risk | (3.60) | |||
| Potential Upside | 4.12 | |||
| Downside Variance | 4.68 | |||
| Semi Variance | 3.85 | |||
| Expected Short fall | (2.10) | |||
| Skewness | 0.5765 | |||
| Kurtosis | 0.8119 |
Medexus Pharmaceuticals Backtested Returns
As of now, Medexus Stock is relatively risky. Medexus Pharmaceuticals has Sharpe Ratio of 0.0509, which conveys that the firm had a 0.0509 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Medexus Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please verify Medexus Pharmaceuticals' Risk Adjusted Performance of 0.0476, downside deviation of 2.16, and Mean Deviation of 1.79 to check out if the risk estimate we provide is consistent with the expected return of 0.12%. Medexus Pharmaceuticals has a performance score of 4 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 0.16, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Medexus Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Medexus Pharmaceuticals is expected to be smaller as well. Medexus Pharmaceuticals right now secures a risk of 2.36%. Please verify Medexus Pharmaceuticals information ratio, downside variance, day median price, as well as the relationship between the treynor ratio and kurtosis , to decide if Medexus Pharmaceuticals will be following its current price movements.
Auto-correlation | -0.16 |
Insignificant reverse predictability
Medexus Pharmaceuticals has insignificant reverse predictability. Overlapping area represents the amount of predictability between Medexus Pharmaceuticals time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Medexus Pharmaceuticals price movement. The serial correlation of -0.16 indicates that over 16.0% of current Medexus Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.16 | |
| Spearman Rank Test | -0.2 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, Medexus Pharmaceuticals has a Net Asset of 171.84 M. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net asset for all Canada stocks is notably lower than that of the firm.
Medexus Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medexus Pharmaceuticals' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medexus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Medexus Pharmaceuticals by comparing valuation metrics of similar companies.Medexus Pharmaceuticals is currently under evaluation in net asset category among its peers.
Medexus Fundamentals
| Return On Equity | 0.009 | ||||
| Return On Asset | 0.0254 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 107.92 M | ||||
| Shares Outstanding | 32.42 M | ||||
| Shares Owned By Insiders | 7.21 % | ||||
| Shares Owned By Institutions | 3.35 % | ||||
| Number Of Shares Shorted | 102.71 K | ||||
| Price To Book | 1.29 X | ||||
| Price To Sales | 0.88 X | ||||
| Revenue | 108.33 M | ||||
| Gross Profit | 63.95 M | ||||
| EBITDA | 16.81 M | ||||
| Net Income | 2.25 M | ||||
| Cash And Equivalents | 23.97 M | ||||
| Total Debt | 37.18 M | ||||
| Book Value Per Share | 2.19 X | ||||
| Cash Flow From Operations | 24.03 M | ||||
| Short Ratio | 2.48 X | ||||
| Earnings Per Share | 0.01 X | ||||
| Target Price | 6.89 | ||||
| Number Of Employees | 91 | ||||
| Beta | 1.98 | ||||
| Market Capitalization | 91.1 M | ||||
| Total Asset | 171.84 M | ||||
| Retained Earnings | (61.99 M) | ||||
| Working Capital | (16.74 M) | ||||
| Net Asset | 171.84 M |
About Medexus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medexus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medexus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medexus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Medexus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medexus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medexus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Medexus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medexus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medexus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medexus Pharmaceuticals to buy it.
The correlation of Medexus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medexus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medexus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medexus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Medexus Stock
Medexus Pharmaceuticals financial ratios help investors to determine whether Medexus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medexus with respect to the benefits of owning Medexus Pharmaceuticals security.